| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | 39.38% | -22.68% | — | — |
| EBITDA Margin | — | — | — | — | 39.39% | -22.64% | — | — |
| Net Margin | — | — | — | — | 34.49% | -22.51% | — | — |
| Current Ratio | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | — |
| Quick Ratio | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | — |
| Debt / Equity | — | — | — | — | — | — | — | — |
| ROE | -57.49% | -38.37% | -24.49% | -18.09% | 17.07% | -2.00% | 28.31% | — |
| ROA | -50.23% | -36.24% | -22.85% | -17.39% | 15.68% | -1.27% | -63.58% | — |
| Asset Turnover | — | — | — | — | 0.45 | 0.06 | — | — |
| Book Value / Share | 3.38 | 5.21 | 6.66 | 7.69 | 8.05 | 25.37 | -4.91 | — |
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections. Its primary product candidate, bemnifosbuvir, a nucleotide NS5B inhibitor, targets COVID-19 caused by SARS-CoV-2 and its variants. The company is also advancing bemnifosbuvir in combination with ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment, with this regimen currently in Phase 3 clinical trials. Additionally, Atea Pharmaceuticals develops AT-587 for chronic hepatitis E virus infection, which is in Phase 1 trials. Operating within the biotechnology sector of healthcare, the company holds a license agreement with MSD International GmbH for ruzasvir's development, manufacture, and commercialization. Founded in 2012 and headquartered in Boston, Massachusetts, Atea Pharmaceuticals plays a key role in advancing innovative oral therapies for viral diseases affecting global patient populations.